Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Radiation Oncology

Topics

Engineering

Cancer Oncology

Medicine

Internal Medicine

Surgery

Show all topics

DOI

10.1186/s13014-024-02581-9

License

CC-BY-NC-ND